Immuneering Corporation announced the granting of a U.S. composition of matter patent for its cancer drug, atebimetinib, in July. This patent is expected to provide exclusivity until 2042, with potential for patent term extension. Atebimetinib, a deep cyclic inhibitor administered as a once-daily pill, aims to offer longer-lasting benefits by overcoming resistance mechanisms in cancer treatment. Additional patent applications for atebimetinib are currently pending, with expiration anticipated into 2044.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.